Welcome everybody to our third session this morning at the Goldman Sachs Healthcare Conference.
My name is Christian Butani along with the team, especially the team that's based in London, Shan Kotadia. Seth James, thank you very much. We're very pleased that Glaxo Smith Kline, GSK can join us today.
Today we have Tony Wood who is the chief scientific officer. The focus of our conversation. There's so much we can always talk about.
With GSK in terms of portfolio strategy, etc. But I always like to make sure that we focus the relatively short time that we have here, 30 minute discussion to being able to go a little bit more into.
There's a lot of critical areas from the clinical development standpoint in the pipeline that is really sort of your power alley. And then we're also going to beg you to ask and comment on some things that are clearly relevant from that pipeline standpoint of the HIV side. But to begin with, just to familiarise the room a little bit about who we're talking to, tell us about you, your professional journey.
OK, so first of all, hi everyone. Pleased to be here. Sorry, we're just a few minutes late. So yeah, my professional journey. I'm I'm now more than 30 years in, in, in the industry. I guess I'd describe myself as a a drug hunter and a technologist.
Six now those years at GSK, before that, 25 years at Pfizer, I grew up. I initially initially as a medicinal chemist, then LED technology groups, history and HIV. I discovered in HIV medicine and my my early career and through that career.
Advisor increasingly was involved not just with technology and therapeutic area focus, but also later stage development on large scale development platforms and led their immunology group for a little while and then six years ago.
Moved to GSK. What I what? I saw there was an opportunity to lead a broader technology platform with an organisation that had a good track record of applying technologies. I joined just about the same time as Hal did and so he and I were sort of part of that last five year journey of.